Skip to main content
Methotrexate (MTX) remains the cornerstone of rheumatoid arthritis (RA) treatment, yet it remains unclear as to how to predict who will respond to it. Two studies presented at ACR (Abstracts 2639 and 2643) suggest the answer may be hiding in the gut.
Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025.  Below are several of the best abstracts from Day 3, as chosen by our outstanding faculty.
At ACR 2025, the session โ€œ27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersectโ€ invited the audience to view rheumatic disease through the lens of biological aging and to consider how nutrition and exercise can serve as integrative lifestyle interventions.
A deep dive into Lupus ๐Ÿ”ฌ
Abstract 2601: Single-cell insights in SLE & pre-clinical autoimmunity
๐Ÿ”น Plasmablast

Akhil Sood MD, MS AkhilSoodMD

11 months ago
A deep dive into Lupus ๐Ÿ”ฌ Abstract 2601: Single-cell insights in SLE & pre-clinical autoimmunity ๐Ÿ”น Plasmablast expansion โ†’ high disease activity & SLE risk ๐Ÿ”น Metabolic activity varies by cell type ๐Ÿ”น Established disease: โ†‘ glycolysis & OxPHOS changes @RheumNow #ACR25
Head to head study of Secukinumab vs Ustekinumab. In TNFi-experienced PsA patients, the AgAIN trial shows secukinumab pe

Antoni Chan MD (Prof) synovialjoints

11 months ago
Head to head study of Secukinumab vs Ustekinumab. In TNFi-experienced PsA patients, the AgAIN trial shows secukinumab performed better than ustekinumab in HAQ-DI response (57.1% vs 27.0%, p=0.002) and across all endpoints (joint counts, pain, and skin outcomes). Fewer https://t.co/CDCWkLF5TW
Abstract 2360: Single-center lupus pregnancy cohort found that:
๐Ÿ”น Absence of DORIS remission associated w/ adverse pr

Akhil Sood MD, MS AkhilSoodMD

11 months ago
Abstract 2360: Single-center lupus pregnancy cohort found that: ๐Ÿ”น Absence of DORIS remission associated w/ adverse pregnancy outcomes (Pre-term, Pre-eclampsia) ๐Ÿ”น This is along with known risk factors: antihypertensive use, prior nephritis, active disease @RheumNow #ACR25 https://t.co/STg1NBeFPo
CDAI appropriately guided therapy escalation in RA, but not for everyone. Treatment adjustments were less likely in pts

Jiha Lee JihaRheum

11 months ago
CDAI appropriately guided therapy escalation in RA, but not for everyone. Treatment adjustments were less likely in pts with public or no insurance. Even data-driven care can fall short when access barriers persist. @RheumNow #ACR25 Abstract#2616
Reaadmissions in sle pregnancies from 66k patients
Insurance and economics seem to be very important in predictions usin

Bella Mehta bella_mehta

11 months ago
Reaadmissions in sle pregnancies from 66k patients Insurance and economics seem to be very important in predictions using machine learning. Abst#2629 #ACR25 @RheumNow https://t.co/x2oo9TOxoh
In healthy women, preeclampsia was more common with:
- increased calprotectin
- decreased anti-CCP (very low levels)
dur

David Liew drdavidliew

11 months ago
In healthy women, preeclampsia was more common with: - increased calprotectin - decreased anti-CCP (very low levels) during pregnancy & this has good predictive capacity for future preeclampsia. Rheum pathophys can give insights into adjacent pathology #ACR25 ABST2628 @RheumNow https://t.co/7d5YB6n6XJ
In a retrospective TrinetX analysis of 3 year safety outcome in AS, JAKi use was linked to higher mortality and GI bleed

Antoni Chan MD (Prof) synovialjoints

11 months ago
In a retrospective TrinetX analysis of 3 year safety outcome in AS, JAKi use was linked to higher mortality and GI bleeding vs TNFi, but lower malignancy risk. Infection rates were similar, with a trend toward more herpes zoster in JAKi users. Abstract#2633 @RheumNow #ACR25 https://t.co/pPY0wpAKA3
DMARD exposure overall during pregnancy is not associated with severe maternal or neonatal morbidity, in this Ontario co

David Liew drdavidliew

11 months ago
DMARD exposure overall during pregnancy is not associated with severe maternal or neonatal morbidity, in this Ontario cohort. Weโ€™re getting better at finding a balance with DMARDs that is safe for both mother and baby. Blanket resistance is harmful #ACR25 ABST2627 @RheumNow https://t.co/oDOpySGS3N
×